Gevokizumab is under clinical development by Novartis and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gevokizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gevokizumab overview
Gevokizumab (XOMA-052) is developing gevokizumab for the treatment of metastatic colorectal cancer gastroesophageal cancer and colon cancer. XOMA 052 is administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection. XOMA 052 is a potent human engineered IgG2 monoclonal antibody, binds to IL-1 beta, a pro-inflammatory cytokine. The drug candidate was under development for the treatment of Pyoderma gangrenosum (PG), erosive osteoarthritis of the hand (EOA), rheumatoid arthritis, multiple myeloma, Systemic Juvenile Idiopathic Arthritis (SJIA), acne vulgaris , gout, non-infectious uveitis (NIU), Behçet's uveitis, skin ulcer including Pyoderma gangrenosum (PG), non-infectious anterior scleritis, Autoimmune inner ear disease (AIED), type 1 diabetes, cardiovascular disease, polymyositis/dermatomyositis, giant cell arteritis, Schnitzler syndrome, type 2 diabetes, diabetic nephropathy, metastatic colorectal cancer (first and second), metastatic gastroesophageal cancer (second) and metastatic renal cell carcinoma (second and third). It is a new molecular entity (NME).
It was under development for renal cell carcinoma as first line therapy.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Gevokizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
